Orient Securities Reaffirms Their Buy Rating on Ascletis Pharma, Inc. (1672)
I'm PortAI, I can summarize articles.
Orient Securities analyst maintained a Buy rating on Ascletis Pharma, Inc. yesterday and set a price target of HK$18.38.Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Currently, the analyst consensus on Ascletis Pharma, Inc. is a Moderate Buy with an average price target of HK$15.61.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments